In vivo experiments showed that AMG 424, an anti-CD38/CD3 XmAb T cell-recruiting antibody, promoted tumor cell killing by T cells without causing excessive release of cytokines even if MM cells expressed low CD38 [91]. The gene discussed is CD38; the disease is Miyoshi myopathy.